Squarepoint Ops LLC Reduces Stake in United Therapeutics Corporation $UTHR

Squarepoint Ops LLC lessened its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 38.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,351 shares of the biotechnology company’s stock after selling 5,145 shares during the period. Squarepoint Ops LLC’s holdings in United Therapeutics were worth $2,400,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Chung Wu Investment Group LLC acquired a new stake in United Therapeutics during the second quarter worth about $29,000. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. grew its position in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. SVB Wealth LLC acquired a new stake in United Therapeutics during the first quarter worth $32,000. Finally, Geneos Wealth Management Inc. increased its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $416.35, for a total transaction of $9,367,875.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 624,054 shares of company stock valued at $283,834,364 in the last ninety days. Company insiders own 10.30% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research analyst reports. Oppenheimer increased their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research note on Monday, December 8th. Cantor Fitzgerald boosted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Finally, HC Wainwright lifted their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $505.00.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $510.94 on Thursday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $513.93. The firm has a 50 day simple moving average of $460.85 and a 200-day simple moving average of $378.34. The firm has a market cap of $22.00 billion, a price-to-earnings ratio of 19.36, a PEG ratio of 4.96 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the business earned $6.39 EPS. Equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.